vs
Side-by-side financial comparison of Masco (MAS) and ResMed (RMD). Click either name above to swap in a different company.
Masco is the larger business by last-quarter revenue ($1.9B vs $1.4B, roughly 1.3× ResMed). ResMed runs the higher net margin — 27.6% vs 11.9%, a 15.7% gap on every dollar of revenue. On growth, ResMed posted the faster year-over-year revenue change (11.0% vs 6.5%). Over the past eight quarters, ResMed's revenue compounded faster (7.8% CAGR vs -4.2%).
Masco Corporation is an American manufacturer of products for the home improvement and new home construction markets. Comprising more than 20 companies, the Masco conglomerate operates nearly 60 manufacturing facilities in the United States and over 20 in other parts of the world. Since 1969 it trades on the NYSE. Under the leadership of Richard Manoogian, the company grew exponentially and subsequently joined the Fortune 500 list of largest U.S. corporations.
ResMed Inc. is a medical equipment company based in San Diego, California, and founded in Australia. It primarily provides cloud-connectable medical devices for the treatment of sleep apnea, chronic obstructive pulmonary disease (COPD), and other respiratory conditions. Resmed produced hundreds of thousands of ventilators and bilevel devices to help treat the respiratory symptoms of patients with COVID-19.
MAS vs RMD — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.9B | $1.4B |
| Net Profit | $228.0M | $392.6M |
| Gross Margin | 35.8% | 61.8% |
| Operating Margin | 16.5% | 34.6% |
| Net Margin | 11.9% | 27.6% |
| Revenue YoY | 6.5% | 11.0% |
| Net Profit YoY | 14.5% | 13.9% |
| EPS (diluted) | — | $2.68 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q2 26 | — | $1.4B | ||
| Q1 26 | $1.9B | $1.4B | ||
| Q4 25 | $1.8B | $1.4B | ||
| Q3 25 | $1.9B | $1.3B | ||
| Q2 25 | $2.1B | $1.3B | ||
| Q1 25 | $1.8B | $1.3B | ||
| Q4 24 | $1.8B | $1.3B | ||
| Q3 24 | $2.0B | $1.2B |
| Q2 26 | — | $392.6M | ||
| Q1 26 | $228.0M | $398.7M | ||
| Q4 25 | $165.0M | $392.6M | ||
| Q3 25 | $189.0M | $348.5M | ||
| Q2 25 | $270.0M | $379.7M | ||
| Q1 25 | $186.0M | $365.0M | ||
| Q4 24 | $182.0M | $344.6M | ||
| Q3 24 | $167.0M | $311.4M |
| Q2 26 | — | 61.8% | ||
| Q1 26 | 35.8% | 62.2% | ||
| Q4 25 | 33.9% | 61.8% | ||
| Q3 25 | 34.2% | 61.5% | ||
| Q2 25 | 37.6% | 60.8% | ||
| Q1 25 | 35.8% | 59.3% | ||
| Q4 24 | 34.8% | 58.6% | ||
| Q3 24 | 36.6% | 58.6% |
| Q2 26 | — | 34.6% | ||
| Q1 26 | 16.5% | 34.9% | ||
| Q4 25 | 13.8% | 34.6% | ||
| Q3 25 | 15.8% | 33.4% | ||
| Q2 25 | 20.1% | 33.7% | ||
| Q1 25 | 15.9% | 33.0% | ||
| Q4 24 | 15.9% | 32.5% | ||
| Q3 24 | 18.0% | 31.6% |
| Q2 26 | — | 27.6% | ||
| Q1 26 | 11.9% | 27.9% | ||
| Q4 25 | 9.2% | 27.6% | ||
| Q3 25 | 9.9% | 26.1% | ||
| Q2 25 | 13.2% | 28.2% | ||
| Q1 25 | 10.3% | 28.3% | ||
| Q4 24 | 10.0% | 26.9% | ||
| Q3 24 | 8.4% | 25.4% |
| Q2 26 | — | $2.68 | ||
| Q1 26 | — | $2.74 | ||
| Q4 25 | $0.81 | $2.68 | ||
| Q3 25 | $0.90 | $2.37 | ||
| Q2 25 | $1.28 | $2.58 | ||
| Q1 25 | $0.87 | $2.48 | ||
| Q4 24 | $0.85 | $2.34 | ||
| Q3 24 | $0.77 | $2.11 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $1.4B |
| Total DebtLower is stronger | $2.9B | $663.8M |
| Stockholders' EquityBook value | $27.0M | $6.3B |
| Total Assets | $5.2B | $8.5B |
| Debt / EquityLower = less leverage | 109.07× | 0.11× |
8-quarter trend — quarters aligned by calendar period.
| Q2 26 | — | $1.4B | ||
| Q1 26 | — | $1.7B | ||
| Q4 25 | $647.0M | $1.4B | ||
| Q3 25 | $559.0M | $1.4B | ||
| Q2 25 | $390.0M | $1.2B | ||
| Q1 25 | $377.0M | $932.7M | ||
| Q4 24 | $634.0M | $521.9M | ||
| Q3 24 | $646.0M | $426.4M |
| Q2 26 | — | $663.8M | ||
| Q1 26 | $2.9B | $664.1M | ||
| Q4 25 | $2.9B | $403.9M | ||
| Q3 25 | — | $408.7M | ||
| Q2 25 | — | $658.4M | ||
| Q1 25 | — | $663.1M | ||
| Q4 24 | $2.9B | $662.9M | ||
| Q3 24 | — | $667.6M |
| Q2 26 | — | $6.3B | ||
| Q1 26 | $27.0M | $6.5B | ||
| Q4 25 | $-185.0M | $6.3B | ||
| Q3 25 | $-78.0M | $6.1B | ||
| Q2 25 | $-84.0M | $6.0B | ||
| Q1 25 | $-254.0M | $5.5B | ||
| Q4 24 | $-279.0M | $5.3B | ||
| Q3 24 | $-88.0M | $5.2B |
| Q2 26 | — | $8.5B | ||
| Q1 26 | $5.2B | $8.8B | ||
| Q4 25 | $5.2B | $8.5B | ||
| Q3 25 | $5.3B | $8.3B | ||
| Q2 25 | $5.3B | $8.2B | ||
| Q1 25 | $5.1B | $7.6B | ||
| Q4 24 | $5.0B | $7.1B | ||
| Q3 24 | $5.3B | $7.2B |
| Q2 26 | — | 0.11× | ||
| Q1 26 | 109.07× | 0.10× | ||
| Q4 25 | — | 0.06× | ||
| Q3 25 | — | 0.07× | ||
| Q2 25 | — | 0.11× | ||
| Q1 25 | — | 0.12× | ||
| Q4 24 | — | 0.13× | ||
| Q3 24 | — | 0.13× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
